ClinicalTrials.gg
CompletedNCT03159624Updated Jun 28, 2023Results posted

Nasal Septal Flap for Donor Site Reconstruction

An interventional study of Biodesign™ SIS graft and Doyle silastic sheet in Nasal Septum Perforation, sponsored by University of Alabama at Birmingham. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Nov 2014, registered May 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the utility of porcine small intestinal submucosa (SIS) as a graft material that may aid in the natural healing process of freshly exposed bone and cartilage in the nasal cavity.

Read the detailed description

Patients who undergo endoscopic endonasal skull base surgery, and may require nasoseptal flap placement as part of skull base reconstruction, will be informed, consented and enrolled for participation. If the intraoperative decision is ultimately made for harvest and placement of full-length nasoseptal flap by each individual surgeon, patients will then be consecutively, sequentially randomized to use of either:

  • Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone (20 randomly assigned patients)
  • 2x3 cm Biodesign™ SIS perforated mesentery graft surface placement plus overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone. (20 randomly assigned patients)

When used, Biodesign graft will be soaked in sterile saline out of the packaging, and placed as an intact single sheet over the exposed bone nasal septum bone/cartilage (without trimming). For uniformity and ease of future analysis, the bottom edge of the graft will be placed parallel to, and proximal to, the nasal floor cut edge remnant mucosal surface as possible. Except for a thin Doyle silastic sheet to cover the graft site, no additional reinforcement (suture/tissue glue) will be placed for those patients in the Biodesign graft arm.

Time Points and Study Parameters:

  • All enrolled patients will have Doyle silastic sheeting removed only at 2 weeks post-op.
  • All patients will receive 250cc normal saline topical nasal rinses starting at 14 days until 120 days post-op.
  • No topical irrigation additives (budesonide/mupirocin) will be administered over 12 weeks.

All patients will be assessed at 2 weeks, 6 weeks and 12 weeks following randomization and entry into this study.

02

Conditions studied

  • Nasal Septum Perforation

Keywords

  • nasoseptal flap
  • tissue repair
  • wound healing
  • remucosalization
  • upper airway
  • granulation tissue
  • tissue graft
03

In context

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elective transnasal endoscopic skull base surgery where closure with a large nasoseptal flap (NSF) is anticipated (exposure of >75% of the ipsilateral nasal septum bone/cartilage)
  • Patients without nutritional compromise or otherwise debilitated
  • Patients who are able to consent for themselves

Exclusion criteria

Exclusion Criteria:

  • Bilateral nasoseptal flap (NSF) placement in the same operative setting
  • Patients without significant bone/cartilage exposure to incorporate an intact 2x3 cm graft
  • Patients requiring 24 hour supplemental oxygen via nasal cannula
  • Patients who cannot consent for themselves
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Treatment Group

    2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone

    Other: Biodesign™ SIS graft · Other: Doyle silastic sheet

  • Active comparator
    Control Group

    Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone

    Other: Doyle silastic sheet

Interventions

  • OtherBiodesign™ SIS graft

    2x3 cm Biodesign™ SIS perforated mesentery graft

  • OtherDoyle silastic sheet

    Doyle silastic sheet

06

What researchers measure

Primary outcomes

  1. Mean Change in Post-operative Remucosalization at the Donor Site

    Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.

    Time frame: 2 weeks, 6 weeks, 12 weeks

  2. Mean Change in Post-operative Locoregional Crusting at Donor Site

    Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.

    Time frame: 2 weeks, 6 weeks, 12 weeks

  3. Mean Change in Post-operative Edema at the Donor Site

    Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.

    Time frame: 2 weeks, 6 weeks, 12 weeks

07

Results

Posted Sep 16, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreatment GroupControl Group
Started2126
Completed2125
Not completed01

Outcome measures

PrimaryMean Change in Post-operative Remucosalization at the Donor Site

Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.

Time frame:
2 weeks, 6 weeks, 12 weeks
Reported as:
Least squares mean · percentage of remucosalization
Mean Change in Post-operative Remucosalization at the Donor Site
percentage of remucosalizationTreatment GroupControl Group
2 weeks47.8 (40.3 to 55.3)37.8 (31.1 to 44.5)
6 weeks49.7 (41.6 to 57.8)43.5 (36.7 to 50.3)
12 weeks73.9 (63.8 to 83.9)65.3 (56.97 to 73.7)
overall change57.1 (52.1 to 62.2)48.9 (45.1 to 52.7)
PrimaryMean Change in Post-operative Locoregional Crusting at Donor Site

Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.

Time frame:
2 weeks, 6 weeks, 12 weeks
Reported as:
Least squares mean · score on a scale
Mean Change in Post-operative Locoregional Crusting at Donor Site
score on a scaleTreatment GroupControl Group
2 weeks3.50 (2.99 to 4.01)4.22 (3.50 to 4.94)
6 weeks4.22 (3.03 to 5.41)5.2 (4.17 to 6.24)
12 weeks2.64 (1.48 to 3.80)2.92 (2.17 to 3.66)
overall change3.45 (2.97 to 3.93)4.11 (3.63 to 4.59)
PrimaryMean Change in Post-operative Edema at the Donor Site

Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.

Time frame:
2 weeks, 6 weeks, 12 weeks
Reported as:
Least squares mean · score on a scale
Mean Change in Post-operative Edema at the Donor Site
score on a scaleTreatment GroupControl Group
2 weeks3.34 (2.94 to 3.75)3.52 (3.16 to 3.89)
6 weeks3.25 (2.74 to 3.76)3.15 (2.75 to 3.55)
12 weeks2.26 (1.84 to 2.70)2.65 (2.11 to 3.19)
overall change2.95 (2.73 to 3.18)3.11 (2.86 to 3.35)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group0/21 (0%)0/21 (0%)7/21 (33.3%)
Control Group0/26 (0%)0/26 (0%)8/26 (30.8%)
Most frequent other events
Most frequent other events
EventTreatment GroupControl Group
minor septal perforationSkin and subcutaneous tissue disorders4/216/26
development of transverse synechiae between septum and inferior turbinateSkin and subcutaneous tissue disorders3/212/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment GroupControl GroupTotal
<=18 years000
Between 18 and 65 years162339
>=65 years538
Sex: Female, Male
Sex: Female, Male(Participants)Treatment GroupControl GroupTotal
Female151530
Male61117
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment GroupControl GroupTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American4711
White10818
More than one race000
Unknown or Not Reported71017
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nayak JV, Rathor A, Grayson JW, Bravo DT, Velasquez N, Noel J, Beswick DM, Riley KO, Patel ZM, Cho DY, Dodd RL, Thamboo A, Choby GW, Walgama E, Harsh GR, Hwang PH, Clemons L, Lowman D, Richman JS, Woodworth BA. Porcine small intestine submucosal grafts improve remucosalization and progenitor cell recruitment to sites of upper airway tissue remodeling. Int Forum Allergy Rhinol. 2018 Oct;8(10):1162-1168. doi: 10.1002/alr.22156. Epub 2018 Jun 1. PubMed 29856526 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Mar 2016, 16 months.

Results were first posted in Sep 2019, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2017
First posted
May 19, 2017
StartActual
Nov 13, 2014
Primary completionActual
Mar 21, 2016
CompletionActual
Mar 21, 2016
Results first posted
Sep 16, 2019
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03159624
Responsible party
Brad Woodworth, MD (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
May 19, 2017
Start date
Nov 13, 2014
Primary completion
Mar 21, 2016
Completion
Mar 21, 2016
Results posted
Sep 16, 2019
Last update
Jun 28, 2023

Study contacts

Brad Woodworth, MD
principal investigator · University of Alabama at Birmingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion